(Q36934314)

English

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome

scientific article published on 14 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome (English)

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

18

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

10

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

5

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

6

object named as

Elias Jabbour

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Gautam Borthakur

7

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Guillermo Garcia-Manero

1

object named as

Guillermo Garcia-Manero

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

Jorge Eduardo Cortes

11

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

17 August 2017

PMC publication ID

8

object named as

Tapan M Kadia

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Marina Konopleva

9

object named as

Marina Y Konopleva

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

12

object named as

Mark Brandt

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Deborah A McCue

14

object named as

Deborah McCue

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Francesco P Tambaro

2

object named as

Francesco Paolo Tambaro

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

author name string

Nebiyou B Bekele

3

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Hui Yang

4

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Yumin Hu

13

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Willie Mae Newsome

15

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sherry R Pierce

16

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Marcos de Lima

17

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

language of work or name

0 references

publication date

14 May 2012

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

18

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

2204-2210

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Anthracycline dose intensification in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Autophagy fights disease through cellular self-digestion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

29 September 2017

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

27 June 2018

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

27 June 2018

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

27 June 2018

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

4 September 2018

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4879705

4 September 2018

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/22585696

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2011.38.3265

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36934314&oldid=2079294196"